What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

What question did this study set out to answer?

This research evaluates the effect of new or worsening anemia on survival and spleen response in myelofibrosis patients treated with ruxolitinib.

December 8, 2025BloodOpen Access

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

This research evaluates the effect of new or worsening anemia on survival and spleen response in myelofibrosis patients treated with ruxolitinib.
Meta-analysis of studies from databases like PubMed and Embase involving myelofibrosis patients on ruxolitinib.
Inclusion of data from the phase 3 JUMP, COMFORT-I, and COMFORT-II trials, along with a real-world analysis.
Statistical analyses focused on overall survival and changes in ruxolitinib dosing.
New or worsening anemia was linked to a 1.57 times higher mortality risk for nonanemic patients.
Overall survival was significantly worse for patients with baseline or new anemia during treatment.
Patients with new anemia experienced a notable mean decrease in ruxolitinib dose.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Meta-analysis shows worsening anemia increases mortality risk in patients with myelofibrosis treated with ruxolitinib, indicating a need for anemia management.

Cite This Study

Vo et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7bf https://doi.org/10.1182/blood-2025-2031

View Full Paper

Ask AI

Bookmark

Implication

Meta-analysis shows worsening anemia increases mortality risk in patients with myelofibrosis treated with ruxolitinib, indicating a need for anemia management.

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis

Key Points

Discussion

Implication

Cite This Study

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading